ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infiltration features are not comprehensively understood. To address the issue, the present study was initiated to describe the immune infiltrations across LUAD from cellular compositional, functional, and mechanism perspectives.MethodsWe adopted five LUAD datasets (GSE32863, GSE43458, GSE75037, TCGA-LUAD, and GSE72094). Differentially expressed genes between LUAD and controls were selected for co-expression network analysis. Risky immune cell types were determined for classifying LUAD patients as diverse subtypes, followed by a comparison of antitumor immunity and therapeutic response between subtypes. Then, LUAD- and subtype-related key module ge...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates a...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
Lung tissue is abundant with immune cells that form a powerful first defense against exotic particle...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundLung adenocarcinoma (LUAD) contains a variety of genomic and epigenomic abnormalities; the...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates a...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
ObjectiveLung adenocarcinoma (LUAD) is the most prevalent lung cancer subtype, but its immune infilt...
Lung tissue is abundant with immune cells that form a powerful first defense against exotic particle...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundLung adenocarcinoma (LUAD) contains a variety of genomic and epigenomic abnormalities; the...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
Tumor-infiltrating lymphocytes are related to positive clinical prognoses in numerous cancer types. ...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundImmune-related subgroup classification in immune checkpoint blockade (ICB) therapy is larg...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...
Patients with early-stage lung adenocarcinoma (LUAD) exhibit different overall survival (OS) rates a...
BackgroundClinically, only a minority of patients benefit from immunotherapy and few efficient bioma...